FORT LAUDERDALE, Fla. & TORONTO--(BUSINESS WIRE)--Flora Growth Corp. (NASDAQ: FLGC) (“Flora” or the “Company”), a manufacturer and distributor of global cannabis products and brands, reported today its financial and operating results for the six months ended June 30, 2022. All financial information is provided in U.S. dollars unless indicated otherwise.
“In the first half of 2022, Flora delivered on its promise to double revenue compared to the second half of 2021, and we expect to maintain that trajectory to deliver our full year guidance as a result of continued growth in our House of Brands, the launch of several new brands in the United States, and the commencement of sales in our Commercial Wholesale and Life Sciences business,” said Luis Merchan, Chairman and CEO of Flora. “We started 2022 with the integration of both Vessel and JustCBD, and despite macro headwinds in the global markets as well as global cannabis regulations, we are extremely pleased with our growth year-to-date. We are also seeing positive movement in our Life Sciences division with progress on the approval of our clinical trials in the United Kingdom and the acquisition of Masaya, a science-backed, high-potency CBD brand.”
Merchan added: “We continue to prudently manage our overhead and working capital as we expect to improve profitability going forward. With all three of our core pillars generating revenue in the second half of 2022, continued gross margin expansion and a focus on streamlining operating expenses – we believe we have a path to profitability that few global cannabis companies can achieve in this difficult environment. The execution of our key initiatives is a testament to our team’s ability to deliver on plan. We will continue to execute as we focus on profitability and long term value creation.”
H1 2022 Financial Highlights:
- Total revenue for the six months ended June 30, 2022, was $14.9 million, up more than 7x year-over-year and 2x sequentially, with the growth driven by Flora’s House of Brands division, which includes the acquisitions of JustCBD and Vessel.
- Gross profit for the period increased to approximately $6.5 million, up more than 5x year-over-year and 4x sequentially.
- Net loss was approximately $32.7 million compared to a net loss of $5.1 million in H1 2021 and a net loss of $16.2 million in H2 2021. The increase in net loss included a non-cash goodwill impairment charge of $16.0 million related to the Vessel acquisition value, driven by a decline in market conditions (Vessel’s peer group public share prices) and the Company’s stock price.
- Adjusted EBITDA was $(8.2) million compared to $(4.9) million in H1 2021. Adjusted EBITDA margin improved significantly from -233% in H1 2021 to -55% in H1 2022. For a reconciliation of these non-IFRS financial measures to the most directly comparable IFRS financial measures, please see Table 4 under "Reconciliation of IFRS to non-IFRS financial results" included at the end of this release.
- As of June 30, 2022, the Company had approximately $10.3 million in cash compared to $37.6 million on December 31, 2021. The decrease was primarily due to cash paid for the JustCBD acquisition in February 2022, as well as higher operating expenses related to investments in headcount, sales and marketing to deliver on the Company’s growth objectives.
Reaffirms 2022 Outlook
- The Company is reaffirming its 2022 revenue guidance to range between $35.0 million - $45.0 million, projecting growth of approximately 300% - 400% over 2021.
H1 2022 Operating Highlights:
- Completed the acquisition of JustCBD, purchasing the company for $16.0 million in cash and 9.5 million common shares of Flora.
- Following the acquisition of Vessel Brand, Inc. in November 2021, Flora Growth named James Choe as Chief Strategy Officer and Jessie Casner as Chief Marketing Officer.
- Appointed former Director of Cannabis for the Florida Department of Agriculture and Consumer Services, Holly Bell, as Vice President of Regulatory Affairs.
- Signed a distribution agreement with Giant OTG Management to provide access to JustCBD products in U.S. airports.
- Increased presence in Europe with the opening of an office in London, while also receiving approval to sell JustCBD products on Amazon UK. The Company also established a brick-and-mortar JustCBD store in the Czech Republic and intends to launch more stores in Germany through its partnership with Greenyard.
- Acquired CBD brand Masaya to expand its Life Sciences offerings. Masaya formulations were submitted as part of the clinical trial program in partnership with the NHS (National Health Service in the UK) and University of Manchester.
- Completed build out of Flora’s all-outdoor cultivation and on-site extraction facility producing distillates and isolates using flower grown at its outdoor operation in Bucaramanga, Colombia.
-
The Company reorganized its laboratory facilities which now include:
- Flora Lab 1 – cannabis extraction facility in Bucaramanga, Colombia
- Flora Lab 2 – GMP processing facility for cannabis and non-cannabis topicals, phytotherapeutics and OTC medicines in Bogota, Colombia
- Flora Lab 3 – cannabis transformation facility for edibles and other cannabis derivatives in Fort Lauderdale, Florida
- Flora Lab 4 – custom formulations lab for cannabis prescriptions in Bogota, Colombia
Subsequent Announcements:
- Appointed Elshad Garayev to serve as Flora’s Chief Financial Officer. Mr Garayev served in a variety of financial leadership positions at companies such as Amazon, Boeing BP and RPK Capital.
- Appointed Brandon Konigsberg to the Board of Directors, who will serve as Chair of the Audit Committee and as a member of the Compensation Committee. Konigsberg was a former executive at JP Morgan Chase (“JPMC”), and has held various leadership roles, including CFO and COO for several growing and turnaround business units.
- Entered into an agreement with Pharma Indigena Misak Manasr Sas (“Manasr”), the largest indigenous tribe in Colombia, to commercialize and sell cannabis products domestically and internationally in partnership with the Misak people.
Earnings Call: August 15, 2022, at 4:30pm ET
Flora will host its H1 2022 earnings call via webcast today at 4:30 P.M. ET. During the webcast, Flora management will discuss its financial and operating results, and will also provide comments on the Company’s 2022 commercial operation, house of brands and life sciences strategies. Following the presentation, Flora will host a Q&A session.
Live Audio Webcast Details
Date: Monday, August 15, 2022
Time: 4:30 p.m. ET
Online Participant Link: https://www.floragrowth.com/flgc-h1-2022-earnings-call/
The recording will be available on the Company’s Investor Center page until June 2023.
The live webcast will be available online through the above participant link and will be archived and available on the Company’s website within approximately 24 hours. If any member of the investment community needs access to a phone dial-in, please email flora@cmwmedia.com and one will be provided.
About Flora Growth Corp.
Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands, designed to deliver the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands, and life sciences divisions. Visit www.floragrowth.com or follow @floragrowthcorp on social media for more information.
Cautionary Statement Concerning Forward-Looking Statements
This press release contains ‘‘forward-looking statements,’’ as defined by federal securities laws. Forward-looking statements reflect Flora’s current expectations and projections about future events at the time, and thus involve uncertainty and risk. The words “believe,” “expect,” “anticipate,” “will,” “could,” “would,” “should,” “may,” “plan,” “estimate,” “intend,” “predict,” “potential,” “continue,” and the negatives of these words and other similar expressions generally identify forward looking statements. Such forward-looking statements are subject to various risks and uncertainties, including those described under the section entitled “Risk Factors” in Flora’s Annual Report on Form 20-F filed with the SEC on May 9, 2022, as such factors may be updated from time to time in Flora’s periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in Flora’s filings with the SEC. While forward-looking statements reflect Flora’s good faith beliefs, they are not guarantees of future performance. Flora disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Flora (or to third parties making the forward-looking statements).
About non-IFRS financial measures
To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with International Financial Reporting Standards ("IFRS"), we use the following non-IFRS financial measures: Adjusted EBITDA and Adjusted EBITDA margin.
- Adjusted EBITDA is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates adjusted EBITDA as total net loss, plus (minus) income taxes (recovery), plus (minus) interest expense (income), plus depreciation and amortization, plus (minus) non-operating expense (income), plus share based compensation, plus impairment charges, plus (minus) fair value adjustments on investments, plus charges related to the flow-through of inventory step-up on business combinations, plus other acquisition and transaction costs, plus (minus) non-cash fair value adjustments on the sale of inventory and biological assets.
- Adjusted EBITDA margin % is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates adjusted EBITDA margin % as adjusted EBITDA, as described above, divided by revenue for the period.
Table 1. Consolidated Statements of Financial Position
Flora Growth Corp. |
||||||
Interim Condensed Consolidated Statements of Financial Position |
||||||
(Unaudited - Prepared by Management) |
||||||
(in thousands of United States dollars) |
||||||
As at: |
|
June 30, 2022 |
|
December 31, 2021 |
||
ASSETS |
|
|
|
|
||
Current |
|
|
|
|||
Cash |
$ |
10,268 |
|
$ |
37,614 |
|
Restricted cash |
|
1 |
|
|
2 |
|
Trade and amounts receivable |
|
5,092 |
|
|
5,324 |
|
Loans receivable and advances |
|
262 |
|
|
273 |
|
Prepaid expenses |
|
2,224 |
|
|
1,700 |
|
Biological assets |
|
14 |
|
|
37 |
|
Inventory |
|
9,295 |
|
|
2,993 |
|
Total current assets |
|
27,156 |
|
|
47,943 |
|
Non-current |
|
|
||||
Property, plant and equipment |
|
4,565 |
|
|
3,750 |
|
Right of use assets |
|
3,639 |
|
|
1,229 |
|
Intangible assets |
13,432 |
|
|
9,736 |
|
|
Goodwill |
28,666 |
|
|
20,054 |
|
|
Investments |
1,337 |
|
|
2,670 |
|
|
Other Assets |
|
273 |
|
|
97 |
|
Total assets |
$ |
79,068 |
|
$ |
85,479 |
|
LIABILITIES |
|
|
|
|
||
Current |
|
|
||||
Trade payables and accrued liabilities |
$ |
7,401 |
|
$ |
5,628 |
|
Current portion of long term debt |
|
10 |
|
|
18 |
|
Current portion of lease liability |
|
1,120 |
|
|
412 |
|
Other accrued liabilities |
|
20 |
|
|
61 |
|
Total current liabilities |
|
8,551 |
|
|
6,119 |
|
Non-current |
|
|
||||
Non-current debt |
|
138 |
|
|
- |
|
Non-current lease liability |
|
2,441 |
|
|
908 |
|
Deferred tax |
|
1,511 |
|
|
1,511 |
|
Other long term liabilities |
|
3,958 |
|
|
- |
|
Total liabilities |
|
16,599 |
|
|
8,538 |
|
SHAREHOLDERS' EQUITY |
|
|
||||
Share capital |
|
119,300 |
|
|
102,428 |
|
Options |
|
6,611 |
|
|
3,712 |
|
Warrants |
|
10,047 |
|
|
10,670 |
|
Accumulated other comprehensive loss |
|
(1,675 |
) |
|
(1,108 |
) |
Deficit |
|
(71,512 |
) |
|
(38,536 |
) |
Non-controlling interest |
|
(302 |
) |
|
(225 |
) |
Total shareholders' equity |
|
62,469 |
|
|
76,941 |
|
Total liabilities and shareholders' equity |
$ |
79,068 |
|
$ |
85,479 |
|
The accompanying notes are an integral part of these interim condensed consolidated financial statements.
Table 2. Consolidated Statements of Loss.
Flora Growth Corp. |
|||||||
Interim Condensed Consolidated Statements of Loss and Comprehensive Loss |
|||||||
(Unaudited - Prepared by Management) |
|||||||
(in thousands of United States dollars, except per share amounts which are in thousands of shares) |
|||||||
|
|
For the six months
|
For the six months
|
||||
Revenue |
|
$ |
14,917 |
|
$ |
2,118 |
|
Cost of sales |
|
|
8,415 |
|
|
1,106 |
|
Gross profit before gain on fair value of biological assets |
|
|
6,502 |
|
|
1,012 |
|
Unrealized gain on changes in fair value of biological assets |
|
|
46 |
|
|
- |
|
Realized fair value amounts included in inventory sold |
|
|
(2 |
) |
|
- |
|
Gross Profit |
|
|
6,546 |
|
|
1,012 |
|
Operating Expenses |
|
||||||
Consulting and management fees |
|
|
5,243 |
|
|
2,262 |
|
Professional fees |
|
|
2,096 |
|
|
766 |
|
General and administrative |
|
|
2,429 |
|
|
1,481 |
|
Promotion and communication |
|
|
4,719 |
|
|
1,180 |
|
Travel expenses |
|
|
601 |
|
|
143 |
|
Share based compensation |
|
|
2,855 |
|
|
95 |
|
Research and development |
|
|
422 |
|
|
85 |
|
Depreciation and amortization |
|
|
1,712 |
|
|
119 |
|
Bad debt expense |
|
|
405 |
|
|
100 |
|
Goodwill impairment |
|
|
16,000 |
|
|
- |
|
Other expenses (income), net |
|
|
1,178 |
|
|
(67 |
) |
Total operating expenses |
|
|
37,660 |
|
|
6,164 |
|
Operating Loss |
|
|
(31,114 |
) |
|
(5,152 |
) |
Interest expense |
|
|
69 |
|
|
64 |
|
Foreign exchange loss (gain) |
|
|
200 |
|
|
(78 |
) |
Unrealized loss on fair value of investments |
|
|
1,333 |
|
|
- |
|
Net loss before income taxes |
|
|
(32,716 |
) |
|
(5,138 |
) |
Income tax benefit |
|
|
- |
|
|
- |
|
Net loss for the period |
|
$ |
(32,716 |
) |
$ |
(5,138 |
) |
Other comprehensive loss |
|
||||||
Exchange differences on foreign operations |
|
$ |
567 |
|
$ |
200 |
|
Total comprehensive loss for the period |
|
$ |
(33,283 |
) |
$ |
(5,338 |
) |
|
|||||||
Net loss attributable to: |
|
||||||
Flora Growth Corp. |
|
$ |
(32,611 |
) |
$ |
(5,097 |
) |
Non-controlling interests |
|
|
(105 |
) |
|
(41 |
) |
Comprehensive loss attributable to: |
|
||||||
Flora Growth Corp. |
|
$ |
(33,178 |
) |
$ |
(5,297 |
) |
Non-controlling interests |
|
|
(105 |
) |
|
(41 |
) |
Basic and diluted loss per share attributable to Flora Growth Corp. |
|
$ |
(0.42 |
) |
$ |
(0.13 |
) |
Weighted average number of common shares
|
|
|
76,944 |
|
|
39,604 |
|
The accompanying notes are an integral part of these interim condensed consolidated financial statements.
Table 3. Consolidated Statements of Cash Flows.
Flora Growth Corp. |
|||||||
| Interim Condensed Consolidated Statement of Cash Flows | |||||||
(Unaudited - Prepared by Management) |
|||||||
(in thousands of United States dollars) |
|||||||
|
|
For the six months
|
For the six months
|
||||
Cash flows from operating activities: |
|
||||||
Net loss |
|
$ |
(32,716 |
) |
$ |
(5,138 |
) |
Adjustments to net loss: |
|
||||||
Depreciation and amortization |
|
|
1,712 |
|
|
119 |
|
Stock-based compensation |
|
|
3,044 |
|
|
95 |
|
Impairments |
|
|
16,000 |
|
|
- |
|
Changes in fair value of investments and biological assets |
|
|
1,287 |
|
|
- |
|
Bad debt expense |
|
|
405 |
|
|
100 |
|
Interest expense |
|
|
56 |
|
|
15 |
|
Income tax benefit |
|
|
- |
|
|
- |
|
Income tax (paid) received |
|
|
- |
|
|
- |
|
|
|
|
(10,212 |
) |
|
(4,809 |
) |
Net change in non-cash working capital: |
|
||||||
Trade and other receivables |
|
|
802 |
|
|
(772 |
) |
Inventory |
|
|
(699 |
) |
|
(421 |
) |
Prepaid expenses and other assets |
|
|
(33 |
) |
|
(1,415 |
) |
Trade payables and accrued liabilities |
|
|
(341 |
) |
|
1,647 |
|
Net cash used in operating activities |
|
|
(10,483 |
) |
|
(5,770 |
) |
|
|
|
|||||
Cash flows from financing activities: |
|
||||||
Common shares issued |
|
|
- |
|
|
16,664 |
|
Equity issue costs |
|
|
(75 |
) |
|
(2,024 |
) |
Exercise of warrants and options |
|
|
168 |
|
|
60 |
|
Repayments of lease liability |
|
|
(420 |
) |
|
(61 |
) |
Common shares repurchased |
|
|
(250 |
) |
|
- |
|
Interest paid |
|
|
(69 |
) |
|
- |
|
Loan borrowing (repayments) |
|
|
130 |
|
|
(220 |
) |
Net cash (used) provided by financing activities |
|
|
(516 |
) |
|
14,419 |
|
|
|
|
|
||||
Cash flows from investing activities: |
|
||||||
Loans provided |
|
|
- |
|
|
(275 |
) |
Loan repayments received |
|
|
- |
|
|
224 |
|
Purchases of property, plant and equipment and other assets |
|
|
(722 |
) |
|
(1,384 |
) |
Purchase of investments |
|
|
- |
|
|
(2,430 |
) |
Business and asset acquisitions, net of cash acquired |
|
|
(15,457 |
) |
|
(1,306 |
) |
Net cash used in investing activities |
|
|
(16,179 |
) |
|
(5,171 |
) |
|
|
|
|
||||
Effect of exchange rate on changes on cash |
|
|
(168 |
) |
|
(195 |
) |
|
|
|
|
||||
Change in cash during the period |
|
|
(27,346 |
) |
|
3,283 |
|
Cash and cash equivalents at beginning of period |
|
|
37,614 |
|
|
15,523 |
|
Cash and cash equivalents at end of period |
|
$ |
10,268 |
|
$ |
18,806 |
|
Supplemental disclosure of non-cash activities |
|
|
|
||||
Right of use assets and lease liabilities acquired |
|
$ |
2,053 |
|
$ |
- |
|
Common shares issued for business combinations |
|
|
14,917 |
|
|
- |
|
The accompanying notes are an integral part of these interim condensed consolidated financial statements.
Table 4. Reconciliation of IFRS to non-IFRS financial results.
Adjusted EBITDA (non-IFRS measure) reconciliation to net loss and Adjusted EBITDA margin to net income (loss) margin. The reconciliation of the Company’s Adjusted EBITDA, a non-IFRS financial measure, to net loss, the most directly comparable IFRS financial measure, for the six months ended June 30, 2022, and June 30, 2021 is presented in the table below:
(In thousands of United States dollars) |
For the six months
|
For the six months
|
||||
Net loss for the period |
$ |
(32,716 |
) |
$ |
(5,138 |
) |
Income tax expense (benefit) |
|
- |
|
|
- |
|
Interest expense |
|
69 |
|
|
65 |
|
Depreciation and amortization |
|
1,712 |
|
|
119 |
|
Non-operating expense (1) |
|
200 |
|
|
(78 |
) |
Share based compensation |
|
3,044 |
|
|
95 |
|
Impairments (2) |
|
16,000 |
|
|
- |
|
Unrealized loss on fair value of investments |
|
1,333 |
|
|
- |
|
Charges related to the flow-through of inventory step-up on business combinations |
|
1,631 |
|
|
- |
|
Other acquisition and transaction costs |
|
559 |
|
|
- |
|
Non-cash fair value adjustments on the sale of inventory and biological assets |
|
(44 |
) |
|
- |
|
Adjusted EBITDA |
$ |
(8,212 |
) |
$ |
(4,937 |
) |
Adjusted EBITDA Margin % |
|
-55.1 |
% |
|
-233.1 |
% |
|
|
(1) |
|
Non-operating expense includes foreign exchange gain (loss). |
|
|
(2) |
|
Impairments include goodwill impairment. |
